New approach to protect brain cells in Alzheimer's

Researchers have discovered a method to protect neurons from damage caused by Alzheimer's disease without targeting the tau protein, which is a key marker of the disease. This approach uses an antibody that blocks the CXCR3 receptor, which plays a role in guiding immune cells called T lymphocytes toward the brain.

Immune system involvement in brain damage

Recent studies suggest that the immune response against tau protein might contribute to neuronal damage in Alzheimer's. While existing treatments focus on beta-amyloid, strategies targeting tau are still under development. However, these treatments do not fully stop the disease or prevent brain cell loss.

Mouse study shows brain tissue preservation

In a study on mouse models of tauopathy, scientists found that blocking the CXCR3 receptor reduced the number of T lymphocytes entering the brain. This treatment preserved approximately 40% more brain tissue in memory-related regions compared to untreated mice. The treated mice also showed better performance in memory tests.

Immune response may not require eliminating tau

The results suggest that the immune system's reaction to tau protein could contribute to brain damage, even if the tau itself is not eliminated. The antibody treatment did not change tau levels but still protected neurons. This could offer a new therapeutic angle without the need to remove the protein.

Potential advantages of the new strategy

According to the study's lead author, David M. Holtzman, the approach has significant advantages. The drug does not need to cross the blood-brain barrier, which is a major challenge for many treatments. This could make the therapy more practical and potentially safer for patients.

Need for further research in humans

While the findings are promising, they were based on experiments with mice. Researchers emphasize the need for further studies to determine if this strategy is safe and effective in humans. The next step is to test the approach in clinical trials to see if it can be applied to people with Alzheimer's disease.